ARX788: Phase I started

Ambrx and Zhejiang began an open-label, Australian and New Zealand Phase I trial to evaluate 0.33, 0.66, 1.3, 2.2, 2.9 and 3.8 mg/kg IV ARX788 every 3 weeks in 80 patients. In 2013, Ambrx and Zhejiang...